Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Approvals Analysis: Eight Brain Device Approvals Mark Neurotech November

Executive Summary

Medtech Insight's Approvals Tracker reports 22 medical device approvals from outside the United States in November, including 12 CE marks from Europe, plus approvals from Taiwan, Singapore, Japan, India, Canada, Australia and Argentina.

You may also be interested in...

Minute Insight: SonALAsense MR-Guided Ultrasound Drug-Device Combo Trials Get Green Light

SonALAsense has received Safe to Proceed letters from the FDA to begin trials of its ultrasound-activated cancer killing drug.

ISC 2018: DEFUSE 3 Results Bring DAWN Of New Stroke Guidelines

Results of the DEFUSE 3 trial presented at the International Stroke Conference in Los Angeles, along with the previously announced DAWN trial results, support a new recommendation in the American Heart Association/American Stroke Association guidelines on early management of acute ischemic stroke, extending the viable treatment window from six hours to 24 hours in some patients. The change could drive thrombectomy uptake and an aspiration-first approach.

DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More

This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts